|Author||: Emerson C. Perin,Leslie W. Miller,Doris Taylor,James T. Willerson|
|Publisher||: Academic Press|
|Release Date||: 2015-08-21|
|ISBN 10||: 0128018631|
|Pages||: 538 pages|
Stem Cell and Gene Therapy for Cardiovascular Disease is a state-of-the-art reference that combines, in one place, the breadth and depth of information available on the topic. As stem cell and gene therapies are the most cutting-edge therapies currently available for patients with heart failure, each section of the book provides information on medical trials from contributors and specialists from around the world, including not only what has been completed, but also what is planned for future research and trials. Cardiology researchers, basic science clinicians, fellows, residents, students, and industry professionals will find this book an invaluable resource for further study on the topic. Provides information on stem and gene therapy medical trials from contributors and specialists around the world, including not only what has been completed, but also what is planned for future research and trials Presents topics that can be applied to allogeneic cells, mesenchymal cells, gene therapy, cardiomyoctyes, iPS cells, MAPC's, and organogenesis Covers the three areas with the greatest clinical trials to date: chronic limb ischemia, chronic angina, and acute MI Covers the prevailing opinions on how to harness the body’s natural repair mechanisms Ideal resource for cardiology researchers, basic science clinicians, fellows, residents, students, and industry professionals
|Author||: Dennis V. Cokkinos|
|Release Date||: 2014-11-06|
|ISBN 10||: 3319087983|
|Pages||: 610 pages|
The term “Translational Research” reflects today’s integration of basic research (“bench”) findings with the clinical practice of medicine, and in a wider scope the application of results from the individual patient (“bedside”) to entire populations for the improvement of public health. This book offers future researchers a stimulus in many aspects of cardiovascular research, so as to promote their interest in future fields of cardiovascular disease, diagnosis and treatment. Introduction to Translational Cardiovascular Research discusses the fundamental and important aspects of the topic. It describes the renin-angiotensin-aldosterone system, the beta adrenergic receptors and the hypothalamic-pituitary-adrenal axis, while covering genetic polymorphisms both generally and specifically as regards the vascular endothelium and the use of microRNAs. As such, this book will be relevant to young physicians, nurses and other scientists engaged in the clinical cardiovascular field who want to added research-oriented dimension to their efforts towards better understanding and practicing of medicine. It also aims to attract young basic researchers who want to develop a better comprehension of the organism as a whole, man or animal, that they are investigating.
This proposed text is designed to provide a useful and comprehensive resource and state-of-the-art overview to readers about vascular damage potentially induced by antineoplastic drugs. Thanks to more and more effective antineoplastic treatments the survival of cancer patients is enormously increasing, but at the same time it is increasing the burden of related cardiovascular complications that affect morbidity and mortality. On this basis a new branch of cardiology has been developed, that is Cardio-Oncology. The aim is to prevent cardiovascular complications related to cancer therapy and to facilitate and avoid interruption of antineoplastic drugs due to the occurrence of cardiovascular damage. An increasing attention has been given to cardiac damage, while, until today, vascular complications have been poorly evaluated. The aim of this book is to focus on vascular complications related to cancer treatment, to guide the clinician at facing, during his every day practice, cardiovascular toxicity in cancer and hematologic patients. The proposed sections of the book have been structured to review the molecular mechanisms underlying vascular damage induced by new and old treatments, to describe the various manifestations of vascular disease that may range from artery to venous disease (including coronary artery disease, peripheral arterial disease, venous thromboembolism and pulmonary hypertension), and to provide advice to monitor patients undergoing onco-hematologic treatments in order to prevent and eventually manage vascular damage.This book will address resident and fellow physicians, medical oncologists, cardiologists, general practitioners and all those who take care of these patients.All invited authors will be recognized experts in their field, and leading international researchers on these topics. The editor has worked with these expert colleagues on a variety of other projects. The authors will provide their manuscript according to current literature and clinical research studies. The book does not seek to duplicate or replace other current resources. Rather, it will create a comprehensive yet concise resource on this emerging topic that is not adequately covered by any current literature.
|Author||: George Hunter|
|Release Date||: 1987|
|Pages||: 58 pages|
The Social Security Administration (SSA) uses a screening tool called the Listing of Impairments to identify claimants who are so severely impaired that they cannot work at all and thus immediately qualify for benefits. In this report, the IOM makes several recommendations for improving SSA's capacity to determine disability benefits more quickly and efficiently using the Listings.
|Author||: Institute of Medicine,Board on Health Sciences Policy,Committee on the Treatment of Cardiac Arrest: Current Status and Future Directions|
|Publisher||: National Academies Press|
|Release Date||: 2015-09-29|
|ISBN 10||: 030937202X|
|Pages||: 456 pages|
Cardiac arrest can strike a seemingly healthy individual of any age, race, ethnicity, or gender at any time in any location, often without warning. Cardiac arrest is the third leading cause of death in the United States, following cancer and heart disease. Four out of five cardiac arrests occur in the home, and more than 90 percent of individuals with cardiac arrest die before reaching the hospital. First and foremost, cardiac arrest treatment is a community issue - local resources and personnel must provide appropriate, high-quality care to save the life of a community member. Time between onset of arrest and provision of care is fundamental, and shortening this time is one of the best ways to reduce the risk of death and disability from cardiac arrest. Specific actions can be implemented now to decrease this time, and recent advances in science could lead to new discoveries in the causes of, and treatments for, cardiac arrest. However, specific barriers must first be addressed. Strategies to Improve Cardiac Arrest Survival examines the complete system of response to cardiac arrest in the United States and identifies opportunities within existing and new treatments, strategies, and research that promise to improve the survival and recovery of patients. The recommendations of Strategies to Improve Cardiac Arrest Survival provide high-priority actions to advance the field as a whole. This report will help citizens, government agencies, and private industry to improve health outcomes from sudden cardiac arrest across the United States.
Cardiac Pacing: An Illustrated Introduction will provide an introduction to all those who have or who are developing an interest in cardiac pacing. At a time in the UK when pacing is being devolved from specialist tertiary cardiac centres to smaller district general hospitals and in the USA where pacemaker implantation is no longer the responsibility of the surgeon and in the domain of cardiologists, there is a need for a text which offers a guide to pacing issues to be used alongside a comprehensive practical training programme in an experienced pacing centre
This concise primer introduces mental health practitioners to the fundamentals of chronic heart disease. It reviews basic etiology and specific methods for assessing and treating comorbid psychological disorders.
Clinical Cardio-oncology is a comprehensive, clinically focused title for cardiologists, oncologists, and specialists in cardio-oncology programs who need up-to-date knowledge about the cardiovascular effects of cancer treatment, especially on long-term cancer survivors. This brand-new resource covers the implementation of cardio-oncology into your practice, while a strong focus on patient management offers helpful information on coordinating care before, during, and after therapy. Its highly organized four-section format allows readers to quickly and easily locate relevant information. Comprised of four sections for quick and easy reference: Oncology and Hematology Principles; Cardiac Complications from Cancer Therapy; Coordination of Care; and Cardio-oncology in Practice. Provides expert wisdom from cardio-oncology authorities around the world, as well as consultation and perspectives from pioneers in the field of oncology. Highlights the principles of cancer therapies, including radiation and tumor therapy, as well as pre-, intra-, and post-therapy cardiology evaluation. Boasts chapters on implementing cardio-oncology into practice: primary cancer centers, comprehensive referral centers, group practices, and educational needs and goals for fellowship programs. Advises on how to coordinate care for the patient at every stage of treatment (pre-therapy, during therapy, after therapy, and end-of-life). Presents detailed information on various cardiac complications from cancer therapy, such as cardiomyopathy, vascular disease, arrhythmias, and hypertension. Teaches the principles of oncology and hematology with coverage of different therapy types and cardiac tumors. Includes a comprehensive drug guide.
|Author||: Guillermo E. Umpierrez|
|Release Date||: 2018-02-09|
|ISBN 10||: 0323583989|
|Pages||: 329 pages|
This issue of Endocrinology and Metabolism Clinics, edited by Dr. Guillermo E. Umpierrez, will focus on Cardiovascular Outcomes of Treatments available for Patients with Type 1 and 2 Diabetes. Topics include--but are not limited to--Diabetes and CAD and PVD; Prediabetes and CVD- DM prevention; Pathogenesis of atherosclerosis/CVD in diabetes Intensive Diabetes Treatment and CV Outcomes in T1D; Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes, Diabetes and Stroke; Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes; Heart Failure in Diabetes Mellitus; Individualizing Glucose Lowering Therapy in the Patient with Diabetes and Heart Disease; Managing Dyslipidemia in Type 2 Diabetes; Blood pressure control and cardiovascular and renal outcomes; Hyperglycemia in acute coronary syndromes; Hospital Glucose Control; Managing Diabetes and cardiovascular risk in chronic kidney disease; and more.
With cardiovascular disease remaining one of the primary causes of morbidity and mortality worldwide, there is a great need to further understand the molecular basis of this disease class and develop new therapeutic or preventative measures. Cardiovascular Diseases: Nutritional and Therapeutic Interventions presents up-to-date information on the pathobiology of cardiovascular diseases, emphasizing emerging therapeutics and nutritional interventions. The book is divided into four parts: epidemiology, epigenetics, pathobiology, and therapies for cardiovascular diseases. Part I details epidemiological studies, highlighting the extent of the clinical problem. Part II describes the genetic and, primarily, epigenetic modifications associated with cardiovascular disease, including the importance of DNA methylation status and the possibility of early intervention using simple dietary modifications. The text also discusses histone modifications associated with disease and potential therapeutic synthetic and dietary compounds such as resveratrol and garlic. Covering the etiology and pathobiology, part III discusses lipid regulation, micro-RNAs, emerging cell-based therapies, and new receptor targets for therapeutics as well as targeted imaging. It also describes the link between cancer therapies and cardiomyopathy and the potential of vitamin C to ameliorate this effect. Part IV focuses on therapeutic and nutritional interventions, namely, stem cell therapies, emerging nanomedicines, and a wide range of dietary interventions. These include general healthy diets, fruits and vegetables, botanicals, effects of specific compounds such as antioxidants, and discussions on garlic, curcumin, and resveratrol. The text also covers lifestyle factors, emphasizing the importance of stress in the occurrence of and meditation and yoga in the management of cardiovascular disease. This book provides a comprehensive reference for clinicians and scientists, combining epidemiology, prevention, and modern treatment strategies.